Cantex starts Ph II glioblastoma trial of CX-02

Cantex Pharmaceuticals Inc. (Weston, Fla.) began a Phase II trial of CX-02 to treat recurrent glioblastoma. The open-label, U.S. trial will evaluate objective response rate (ORR) as the primary endpoint in about 20 patients receiving 80 mg/1.5 mg oral CX-02 thrice daily plus temozolomide for 6 months. Secondary endpoints include progression-free survival (PFS), overall survival (OS) and safety. ...